The relevance of endothelin in central cardiovascular function was studied in urethane-anesthetized Sprague-Dawley rats. Blood pressure (BP) was monitored intra-arterially, and cerebrospinal fluid (CSF) was collected through an intracisternal catheter for radioimmunoassay of endothelin-1 (ET-1). Endothelin levels in the CSF were significantly higher (39±3 pg/ml) than in plasma (10±3 pg/ml, n=11). ET-1 in CSF or plasma was not affected by systemic infusion of saline, but its levels significantly decreased when a sustained increase in BP was elicited with phenylephrine (14±7 pg/ml in the CSF and 6±4 pg/ml in plasma, n =5). In sinoaortic-denervated animals, phenylephrine failed to reduce CSF endothelin levels. In different experiments, intracisternal administration of ET-1 (10 pmol) evoked an initial decrease in BP and heart rate (HR), followed by pronounced hypertension, bradycardia, and, in 70%o of the animals, death from cardiorespiratory failure. Intracisternal administration of endothelin-3 (ET-3, 80 pmol, n =11) evoked only a modest hypotensive and bradycardic response without cardiorespiratory impairment. Microinjection of ET-1 (0.5, 1, 2, 4, and 6 pmol/60 nl) into the nucleus of the solitary tract or area postrema produced a decrease in BP and HR. On the other hand, injection of low concentrations of ET-3 into the nucleus of the solitary tract increased BP and HR (at 2 pmol, 17±3 mm Hg, 14±6 beats per minute, n =7), whereas ET-3 in the area postrema produced a prominent dose-related decrease in BP and HR. In the rostroventrolateral medulla, the lowest doses of ET-1 first modestly increased BP and renal sympathetic nerve activity. These effects were followed by hypotension, bradycardia, increase in respiratory frequency, and further enhancement of sympathetic nerve traffic. In 29%-o of the animals, these effects were followed by cardiorespiratory arrest. The specificity of the cardiovascular response to endothelin was demonstrated by the inhibitory effects of the receptor antagonist BQ-123. These results demonstrate that endothelin has specific cardiovascular effects in the brainstem of the rat and support a role for endothelin in cardiovascular regulation. (Circulation Research 1992;72:20-35) KEY WoRDs * nucleus of the solitary tract respiration * blood pressure E_ ndothelin, a 21-amino acid polypeptide, was first identified as an endothelium-derived contracting factor. The exact structure and amino acid sequence were initially described by Yanagisawa et al' in 1988, with subsequent studies demonstrating that endothelin is an exceptionally potent vasoconstrictor in a wide variety of isolated vessels including coronary,' femoral,' renal,' aortic,2 basilar,3 and mesenteric3 arteries.
E_ ndothelin, a 21-amino acid polypeptide, was first identified as an endothelium-derived contracting factor. The exact structure and amino acid sequence were initially described by , with subsequent studies demonstrating that endothelin is an exceptionally potent vasoconstrictor in a wide variety of isolated vessels including coronary,' femoral,' renal,' aortic,2 basilar,3 and mesenteric3 arteries.
Systemic administration of endothelin induces a sustained increase in arterial blood pressure (BP) in both conscious2,4-6 and anesthetized4,5'7-9 animals. Although it was initially overlooked, the bolus intravenous administration of endothelin evokes a transient depressor response that precedes the sustained increase in area postrema * rostroventrolateral medulla -BP.125710"1 On the other hand, when endothelin is given by constant infusion, only a monophasic pressor effect is observed. 12"13 At least three different isoforms of endothelin have been characterized. Endothelin-1 (ET-1) differs from endothelin-2 (ET-2) by two and from endothelin-3 (ET-3) by six amino acid residues.14 Very few studies, however, have systematically approached the physiological and pharmacological differences of these endothelin isoforms. Most of these experiments suggested the presence of different subtypes of endothelin receptors. For instance, ET-3 is 20 times less potent than ET-1 at contracting rat aortic strips, equipotent at producing the transient fall in BP described above, and three times less potent at causing the subsequent rise.'5 More recently, two different endothelin receptors have been cloned and sequenced,'617 termed ETA (selective for ET-1 and ET-2) and ETB (equally sensitive for all endothelin isoforms).
Because endothelin was initially isolated from vascular endothelial cells, studies of the cardiovascular effects of endothelin did not focus on the central nervous system. However, there are several lines of evidence 21 suggesting that endothelin may function as a neuromodulator within the central nervous system. Autoradiographic studies documented the presence of endothelin binding sites in brain nuclei that participate in cardiovascular function, including the supraoptical and paraventricular nuclei of the hypothalamus, the nucleus of the solitary tract (NTS), the rostroventrolateral medulla (RVLM), and several circumventricular organs. 18"19 In addition, neural, as opposed to vascular, localization of endothelin within the brain has been suggested by immunohistochemistry,20 Northern blot analysis,21 and in situ hybridization techniques.202' Initial pharmacological studies demonstrated that ET-1 administered into the lateral ventricle of rats caused a dose-dependent increase in mean BP, heart rate (HR), and plasma catecholamines.22 Others have shown that higher intracerebroventricular doses of ET-1 cause profound pressor and vasoconstrictor responses that are followed by cardiovascular collapse and death of the animal. 23 The cardiovascular effects of ET-1 in the lateral ventricle can be blocked by the previous administration of phenoxybenzamine,22 diltiazem, or calmodulin antagonists.24 More recently, initial attempts were made to determine the effect of targeted administration of ET-1 into the area postrema (AP)25 and the ventral medulla. 26 In the present study, we investigated the possibility that endothelin affects central cardiovascular function. First, we defined levels of endothelin in the cerebrospinal fluid (CSF) and assessed how the effects of changes in BP modulate central levels of this peptide. Second, we studied the effects of different isoforms of endothelin in the brainstem of normotensive animals on central cardiovascular activity. Overall, the results suggest that endothelin has potent and specific cardiovascular activity in the brainstem.
Materials and Methods General Procedures
Male Sprague-Dawley rats were obtained from Sasco Sprague-Dawley, St. Louis, Mo. They were housed with a light/dark cycle of 12:12 hours and were fed rat chow and tap water ad libitum. Rats were 3-5 months old when used and weighed between 280 and 350 g.
The day of the experiment, the animals were anesthetized with urethane (1.0 g/kg i.p. plus 300 mg/kg i.v.). A polyethylene cannula (PE-50) was placed in the femoral vein for administration of drugs and/or blood sampling. BP was measured directly through a cannula placed into the femoral artery and connected to a Gould P231D pressure transducer and a Gould RS3800 polygraph. HR was monitored continuously by a tachograph preamplifier (model 13-4615-65, Gould) driven by the R wave of the electrocardiographic signal.
CSF Endothelin Levels
After initial instrumentation, the animals were placed in a stereotaxic frame (David Kopf Instruments, Tujunga, Calif.). The cisterna magna was exposed by midline incision through the trapezoidal and rhomboid muscles, keeping the head flexed at 450. The tip of a 10-cm-long polyethylene cannula (PE-10) was inserted through the leptomeninges. This cannula was kept in place by cyanoacrylate biomedical glue. Adequate location of the cannula was verified by efflux of clear CSF. Animals were removed from the stereotaxic frame and placed on a heating pad that kept them at a constant temperature. If traces of blood were observed, the experiment was terminated, and the CSF sample was not included in the final analysis.
After the animals had rested for 1 hour, 250 td CSF was collected over a 30-45-minute control period. The collecting tube was maintained at 0-4°C and contained 25 ,ll protease inhibitor solution (1 mM diisopropylfluorophosphate, 5,000 kallikrein inhibiting units (KIU)/ml aprotinin, and 20 mM EDTA in saline). At the end of this period, 1 ml blood was sampled from the femoral vein, mixed with 0.5 ml of 0.3 M acetic acid, 100 ,ul protease inhibitor solution, and 40 gl of 0.4% Triton X-305, and then centrifuged at 3,000 rpm for 10 minutes. The samples were stored at -70°C for subsequent ET-1 determinations. The red blood cells were reconstituted with warm sterile saline and reinjected to maintain initial volume in the experimental animal. Next, the animals were randomly assigned, either to a group that received a continuous infusion of saline (0.1 ml/min) (n=6) or to another group in which BP was elevated at least 25 mm Hg by a phenylephrine infusion (30 ,ug/kg per minute) (n =5). The infusion period was continued during the time interval necessary to collect at least 250 tl CSF. At the end of this experimental period, another blood sample was obtained for plasma levels of endothelin.
Effects of sinoaortic denervation on CSF endothelin levels. A different group of rats (n = 8) underwent sinoaortic denervation, which was performed according to the method reported by Krieger.27 In brief, the animals were instrumented as described above. In addition, a ventral midline neck incision was made, and the sternocleidomastoid muscles were retracted. The aortic baroreceptors were denervated by bilaterally sectioning the cervical sympathetic trunks, the aortic depressor nerve (when it was identified), and the superior laryngeal nerves. The carotid baroreceptors were denervated by dissecting and stripping the region of the carotid sinus. The rest of the experimental protocol was performed as described before.
Endothelin was measured in plasma and CSF using a sensitive radioimmunoassay as described elsewhere. 28 In brief, the samples were applied to a Bond Elut C8 cartridge (Varian Associates, Inc., Harbor City, Calif.), which had been prewashed successively with 100% acetonitrile/0.1% trifluoroacetic acid (TFA), 100% methanol/0.1% TFA, and 0.1% TFA in water (2.4 ml each). After the sample was applied, the cartridge was washed with 1.6 ml of 0.1% TFA followed by 1.6 ml of 40% MeOH/0.1% TFA. Endothelin was eluted with 1.6 ml of 75% MeOH/0.1% TFA/0.01% Triton X-305. The eluate was concentrated to dryness in a Speed-Vac, and the residue was dissolved in the diluent buffer for radioimmunoassay.
The standard diluent for radioimmunoassay was 0.1 M Tris-acetate (pH 7.4) containing 0.1% bovine serum albumin, 500 KIU/ml aprotinin, 1 
Intracisternal Administration of Endothelin
To determine the cardiovascular effects of endothelin in the cisterna magna, normotensive Sprague-Dawley rats were prepared as above. An intracisternal catheter was maintained patent for administration of artificial CSF or different doses of ET-1 or ET-3. Endothelin isoforms were diluted in artificial CSF to deliver concentrations of 10-80 pmol. In the control period, animals were treated with 10 gul artificial CSF (n=11). In the subsequent period, the animals received either ET-1 (n=7) or ET-3 in increasing cumulative doses (n=4), and the effects on BP and HR were followed for at least 60 minutes.
Intramedullary Administration of Endothelin
Additional groups of rats were placed in the stereotaxic frame, and the dorsal surface of the medulla was exposed by limited craniotomy. For The cannula was lowered into the right NTS using the anteroposterior, mediolateral, and vertical coordinates of 0.0, 0.5, and 0.4-0.55 mm, respectively, or into the AP using coordinates of +0.5, 0.0, and 0.2-0.25 mm, respectively, or into the RVLM area using coordinates of +2.5-2.7, 1.8-2.1, and 2.4-2.8 mm, respectively, using the obex as reference.
Before studying the cardiovascular action of ET-1 or ET-3, the injection sites within the NTS or RVLM were selected by defining the most sensitive location that could be found for the effects of glutamate as characterized previously.29,30 To rule out a possible effect of glutamate on ET effects, a separate group of five animals received ET-1 microinjections into the NTS by use of only stereotaxic coordinates and subsequent histological verification. On different animals, the most sensitive site for the effect of adenosine within the corresponding stereotaxic coordinates for the AP was selected for subsequent endothelin microinjection. We have previously demonstrated an important and specific decrease in BP and HR (at least -29 mm Hg and -50 beats per minute, respectively) after microinjection of adenosine into the AP. 30, 31 For drug administration into brainstem nuclei, the substances were dissolved in sterile saline to final concentrations in a volume not exceeding 60 nl and adjusted to a neutral pH (7.2-7. 3). We30 and others32 have previously reported the absence of significant cardiovascular effects with similar or smaller volumes of saline injected into the AP or in the NTS. To determine the effects of ET-1 or ET-3 in different brainstem nuclei, ascending doses of these isoforms were microinjected into either the AP, NTS, or RVLM of urethaneanesthetized rats at intervals of 30-60 minutes.
Effects of intra-RVLM administration of endothelin on renal sympathetic nerve activity. To elucidate the effects of intra-RVLM microinjection of ET on sympathetic outflow, a group of eight animals was instrumented for recording of renal sympathetic nerve activity (RSNA) as previously described. 30 In brief, a left-sided laparotomy was performed to expose the left renal nerve at the junction of the renal artery and the aorta. The nerve was carefully dissected and placed in situ on bipolar hook electrodes (Teflon-insulated 0.003 -in. stainless steel, Medwire Corp., New York). The site was covered with low viscosity polyvinylsiloxane dental impression material to electrically isolate the nerve-electrode junction. Multiunit recordings were amplified : 100,000 times in two stages by a Gould isolated preamplifier (model 11-5407-58 ) and a Gould universal amplifier (model 13-4615-58) . Nerve activity was full-wave-rectified, integrated, and expressed in arbitrary units proportional to volts-second by a Gould integrator amplifier (model 13-4615-70). Total sympathetic activity (equal to the sum of efferent and afferent activity plus electrical noise) was recorded, and the signal remaining after intravenous administration of hexamethonium (20 mg/ kg) was assumed to represent electrical noise and afferent activity. The magnitude of this signal was considered to be an estimate of "zero" efferent nerve activity, and estimates of efferent nerve activity were obtained by subtracting zero activity from the total recorded activity.
Effects of endothelin on respiration. In a subgroup of animals (n=9), the effects of intra-RVLM administration of ET-1 on respiratory frequency and blood gases were investigated. After induction of anesthesia, the trachea was intubated, and a thermistor probe (YS1 series, model 1-8456-00, Cole-Palmer Instrument Co., Chicago) was placed in the cannulated tracheal tube. Breathing was monitored from the temperature fluctuation in the airway where the probe was located. By using a Gould tachograph, the respiratory rate was derived. In this group, an additional arterial line was placed in the other femoral artery for blood gas determination. After the animals were placed in the stereotaxic frame, the RVLM was identified, and they were rested for 30 minutes; a blood sample was taken ('=0.25 ml) in heparinized capillary tubes, and the same volume was replaced using blood from a donor animal. Blood gases were determined in a Corning 158 pH/blood gas analyzer. After BP and HR were stable, a microinjection of ET-1 (2 pmol) was administered into the RVLM. At the onset and/or the peak of the hemodynamic response, another sample was obtained for blood gas determination. Six more animals were used to assess the cardiovascular effects of endothelin in artificially ventilated animals. In addition to instrumentation similar to that above, the tracheal cannula was connected to a small animal ventilator (model , Harvard Apparatus, South Natick, Mass.) set to a rate of 90 breaths per minute, and ventilation was continued throughout the protocol as described above.
Specificity of the Endothelin Response
To study whether some of the endothelin effects were caused by the intense vasoconstriction that this peptide can cause, we performed a series of experiments with two other vasoconstrictor agents. In the first series, phenylephrine, an a1-adrenergic agonist, was microinjected (into the NTS or RVLM) in ascending doses (58, 580 , and 4,926 pmol), and the hemodynamic effects were followed as with endothelin. In a different set of experiments, we studied the effects of microinjections of a more potent vasoconstrictor for cerebral blood vessels. It has been previously documented that vasopressin is more potent than ET-1 in constricting brain blood vessels. 33 In these studies BP and HR were monitored before and up to 120 minutes after the injection of vasopressin (0.6, 6, and 60 pmol) into the RVLM. This dose range was selected to exceed the one of endothelin.
Integrity of neuronal function. To elucidate whether intraparenchymal administration of endothelin induces neuronal cell death or dysfunction, we studied the integrity of the glutamatergic response in the NTS after the administration of 2 pmol ET-1. In four rats, glutamate (74 pmol/60 nl) was administered into the NTS before and after the administration of 60 nl saline. After recovery, in the same group of rats, ET-1 was microinjected. Glutamate response was again evaluated after 5, Effects of a specific endothelin receptor antagonist. A final set of experiments addressed the possible receptor specificity of the cardiovascular effects of endothelin. Two different groups of animals were used to study the effects of a specific endothelin receptor antagonist. In six animals, ET-1 was microinjected (2 pmol/60 nl) into the NTS before and after similar administration of the pep- 2 nmol/60 nl) or saline. In the other group, the same dose of BQ-123 was microinjected into the RVLM, and the cardiovascular effects were followed for 15 minutes. At the end of this period, ET-1 was also microinjected into the RVLM, and the cardiorespiratory effects were followed for the next 90 minutes.
Histological Localization
After completion of the experiments, 120 nl fast green ink was injected through the cannula, and the animals were perfused with saline followed by a solution of 4% formaldehyde. Sections (40 gim) of the brainstem were stained with cresyl violet, and placement of the pipette tip in the AP, NTS, or RVLM areas was verified by the histological sections ( Figure 1 ). Only results from those animals in which histology documented adequate placement within the appropriate brain nucleus were included for final evaluation.
Drugs and Reagents
The following drugs were used: urethane (Aldrich Chemical Co., Milwaukee, Wis.); L-glutamic acid (NBC, Cleveland, Ohio); adenosine, diisopropylfluorophosphate, aprotinin, and Triton X-305 (Sigma Chemical Co., St. Louis, Mo.); ET-1 and ET-3 (Peptides International, Inc., Louisville, Ky.); acetic acid; normal rabbit plasma Freez, Rogers, Ark.); and rabbit anti-ET-1 serum and arginine vasopressin (Peninsula Laboratories, Inc., Belmont, Calif.). The endothelin antagonist BQ-123 was a generous gift from BANYU Pharmaceutical, Tokyo.
Statistical Analysis
For evaluation of the results, Student's paired t tests or analyses of variance followed by a Dunnett's test for significant differences were used as appropriate. Differences with a value of p<0.05 were taken as significant. All data are presented as mean+SEM.
Results

CSF Endothelin Levels
Our initial experiments determined the concentration of ET-1 in the CSF of normotensive urethane-anesthetized Sprague-Dawley rats. Basal systolic BP, diastolic BP, and HR were 120+6 mm Hg, 75 ±5 mm Hg, and 325±14 beats per minute, respectively (n=11). The level of ET-1 in the CSF was 39+3 pg/ml. This value was significantly higher than in plasma (10+±3 pg/ml, Figure  2 ). In six of these rats, we tested the effects of a subsequent infusion of saline (0.1 ml/min), producing a (Figure 2 ). In contrast, in five rats with phenylephrine-induced hypertension (increase in systolic BP of 35+11 mm Hg and diastolic BP of 25+9 mm Hg and decrease in HR of 29±+15 beats per minute), ET-1 levels fell in the CSF to 14±7 pg/ml and in plasma to 6±4 pg/ml. The decrease in ET-1 concentration was more pronounced in the CSF.
CSF Endothelin Levels in Sinoaortic-Denervated Rats
Twelve rats underwent exposure of baroreceptor nerves; eight had sinoaortic denervation, and four were left with intact nerves to serve as controls. Bolus administration of phenylephrine (5 gg) increased BP and reflexively decreased HR (see Table 1 ). After sinoaortic denervation, an equivalent increase in BP produced by phenylephrine failed to significantly decrease HR. In contrast, in the rats with intact baroreflex, similar bradycardia (-85-+±13 beats per minute) was observed after bolus administration of the pressor agent. The levels of ET-1 in the CSF of sinoaorticdenervated rats, although lower, were not significantly different from those of the control rats (see Table 1 ). On the other hand, sustained hypertension induced by phenylephrine infusion failed to reduce ET-1 levels in the CSF of sinoaortic-denervated rats (Table 1) .
Intracisternal Administration of Endothelin
We next determined the cardiovascular effects of endothelin administration into the cisterna magna. In addition to characterizing the effects of ET-1, we compared its effects with those of ET-3. Administration of 10 gl artificial CSF (over 2 (20 pmol) in the remaining animals produced a similar initial response, followed by a more pronounced hypertensive phase (increase in mean BP by 81±9 mm Hg) and death in all animals.
The initial intracisternal dose of ET-3 (10 pmol) did not produce significant cardiorespiratory changes (n=4). Only the highest dose tested (80 pmol of ET-3) modestly decreased BP (-10+5 mm Hg) and HR (-41±29 beats per minute, n=4, Figure 3 ). The cardiovascular effects of 80 pmol ET-3 were, however, long lasting, and they fully recovered after only 45 minutes of administration. No cardiorespiratory impairment was observed in any of the animals tested with this endothelin isoform. 
Intramedullary Administration of Endothelin
We selected three medullary centers known to be involved in central cardiovascular regulation to characterize the hemodynamic effects of endothelin. We first investigated the effects of endothelin in the NTS. We selected this medullary nucleus because of its impor- tance in reflex cardiovascular function and because this is where the first synapse of the baroreflex is located. 34 
Nucleus of the Solitary Tract
At all doses tested, ET-1 in the NTS decreased BP and HR. The maximal decreases in BP and HR were observed at the 2 pmol dose (-20+7 mm Hg and -50+12 beats per minute, respectively, n =5, Figure 4 ). These effects peaked between 5 and 8 minutes and fully recovered by 25 minutes after ET-1 microinjection ( Figure 5 ). To evaluate the development of tachyphylaxis, 1 pmol ET-1 was microinjected at 15-90-minute intervals. As observed in Table 2 , similar hypotensive and bradycardic effects were observed when ET-1 was microinjected at 30-90-minute intervals. However, with shorter intervals (i.e., 15 minutes), the hypotensive and bradycardic responses were reduced ( Table 2) .
In another group of five animals, ET-1 was microinjected into the NTS without any previous administration of glutamate. No significant changes in the response to ET-1 were observed in this group. The maximal hypotensive (-25 +6 mm Hg) and bradycardic (-41 + 15 beats per minute) effects were observed at the 2 pmol dose and were not significantly different from the group in which glutamate was used to identify the NTS (compare with Figure 4) .
A different cardiovascular profile was observed after administration of ET-3 into the NTS. Low doses of ET-3 in the NTS (0.5-2 pmol, Figure 4 ) increased BP and HR, an effect that was maximal at 2 pmol (17+3 mmHg, 14+6 beats per minute, n=7). Peak changes occurred within 45 seconds and recovered by 15 minutes ( Figure 5 ). Higher ET-3 doses (4 and 6 pmol) modestly decreased BP and HR.
Area Postrema
Although circulating endothelin does not cross the blood-brain barrier in significant concentrations,35 systemic endothelin could affect neuronal function in the brain by acting at sites with a deficient blood-brain barrier such as the AP. We thus characterized the pharmacological responses to ET-1 and ET-3 in this highly vascularized circumventricular organ. Administration of 2 pmol ET-1 in the AP modestly decreased BP and HR (-14+7 mm Hg, -36±+15 beats per minute, n=7). Higher doses produced no additional effects ( Figure 6 ). ET-3 had effects similar to those of ET-1 in this nucleus. In five animals, intra-AP microinjection of ET-3 produced a clear dose-related hypotensive and bradycardic effect ( Figure 6 ). These effects developed rapidly after administration (within 1 minute, Figure 5 ) and were maximal between 4 and 6 pmol. HR. The effects were maximal at the 1-pmol dose, with no clear dose-related effect ( Figure 7 ) and without compromise of respiratory function.
Effects of Intra-RVLMAdministration of Endothelin in Artificially Ventilated Rats
In artificially ventilated rats, we evaluated the cardiovascular effects of ET-1 microinjection (0.5, 1.0, and 6.0 pmol, n =6) into the RVLM. In this group of rats, with a respiratory rate set at 90 breaths per minute, basal mean BP and HR were 83+5 mm Hg and 313±21 beats per minute, respectively. Artificial ventilation did not affect the biphasic blood pressure response of 0.5, 1.0, or 6.0 pmol ET-1 (Figure 8 ). Neither the pressor nor depressor effects were different from those in the spontaneously breathing animals (compare Figure 8 and Table 3 ). Artificial ventilation, on the other hand, blunted the bradycardic response observed during the hypotensive phase. No deaths were observed in these animals.
Effects of Intra-RVLM Administration of Endothelin on Renal Sympathetic Nerve Activity
To elucidate the effects of ET in sympathetic neurotransmission, we instrumented a group of eight rats for the recording of RSNA during intra-RVLM administration of ET-1. Saline microinjection did not modify RSNA or BP (Table 4) . After administration of the lowest dose of ET-1 (0.5 pmol), an increase in renal sympathetic nerve traffic clearly preceded the pressor effect ( Figure 9 ). After this initial response, both BP and RSNA started to decline. During the late phase, however, BP further decreased, whereas RSNA increased to levels that exceeded the initial response (Table 4) . With the two highest doses, no change in BP, HR, or RSNA was observed immediately after microinjection of ET-1 (Table 4) . On the other hand, during the hypotensive response, a pronounced increase in RSNA was observed in all animals. In the rats in which cardiorespiratory collapse was observed, RSNA remained elevated for 3-4 minutes after BP or HR was undetectable and then declined to zero levels.
Effects of Endothelin in Respiration
In additional experiments, we investigated the effects of intra-RVLM ET-1 administration on respiration and arterial blood gases (n=9 In three additional animals in which intra-RVLM microinjection of ET-1 produced cardiorespiratory collapse, BP, HR, and Rf were continuously monitored. As in the previous animals, the initial increase in BP (12±4 mm Hg) was followed by a hypotensive and bradycardic period, during which Rf increased (35+± 13 breaths per minute). In these animals, BP and HR further decreased, Rf remained elevated, but respiration became superficial. This period was followed by abrupt apnea, (Table 5) . At an extremely high concentration (4.9 nmol), phenylephrine in the NTS still did not affect BP and only modestly reduced HR (-16+8 beats per minute, Table 5 ). Administration of similar doses of phenylephrine into the RVLM did not affect basal cardiovascular activity (Table 5 ). In another group of rats, we used a different and more potent cerebral vasoconstrictor. Vasopressin was microinjected in ascending doses into the right RVLM. Again, no significant cardiovascular effects were observed with the lower doses. Only with the highest dose (60 pmol) was a significant decrease in HR observed (Table 5 ).
Integrity of Neuronal Function
In a separate set of experiments, we studied the possibility that ET microinjection may induce brain lesions that contribute to the observed cardiovascular response. After saline administration into the NTS, glutamate decreased BP (-16±4 mm Hg) and HR (-78±14 beats per minute, n=4). These effects were short in duration and fully recovered within 1 minute. (-15±4 mm Hg), which resolved within 45 seconds, followed by a small but more sustained pressor effect (5+2 mm Hg), which returned to basal levels within the next 7-8 minutes. Subsequent administration of ET-1 failed to affect either BP (-1+3 mm Hg) or HR (-6+9 beats per minute). The cardiovascular response to ET-1 remained inhibited up to 90 minutes after the administration of the endothelin-receptor antagonist.
The effects of BQ-123 in the RVLM were studied in a final group of six rats and compared with a control 30T group that was pretreated with saline (n=6). In the control group, saline did not affect BP, HR, or the subsequent biphasic response to 2 pmol ET-1 ( Figure  10 ). In contrast, administration of 2 nmol BQ-123 evoked a pressor and bradycardic effect (11+1 mm Hg and -15+6 beats per minute for BP and HR, respectively). After recovery of BP and HR (13+3 minutes), the pressor and hypotensive effects of ET-1 were completely inhibited (Figure 10 ). In none of the animals that were pretreated with BQ-123 was cardiorespiratory failure observed after the administration of ET-1.
[-E 20+ B.P. ET-3 (pmol) FIGURE 7. Graphs showing hypertensive and tachycardic effects of different doses of endothelin-3 (ET-3) administered into the rostroventrolateral medulla of anesthetized rats. ET-3 was microinjected into the right rostroventrolateral medulla. Vertical bars represent SEM (n=7). Basal blood pressure (B.P.) and heart rate (H.R.) were 91±4 mm Hg and 322+±8 beats per minute (bpm), respectively. *p<0.05 vs. control values. We first documented the presence of endothelin in the CSF immediately adjacent to the lower brainstem.
Our data indicate that the concentration of ET-1-like immunoreactivity in plasma is significantly lower than in the CSF. These results are in agreement with previous reports indicating a higher concentration of ET-1 in the CSF than in the plasma of healthy volunteers,42 patients with cerebrovascular disease,43 or patients with major depression.42 On the other hand, these findings were not corroborated in a recent study by endothelin measurements in CSF samples from subjects with different pathophysiological states that required diagnostic lumbar puncture or lumbar puncture for anesthesia.44 Although it remains to be established whether underlying pathological conditions explain the differences in human endothelin CSF levels among these reports, our present results clearly indicate that systemic changes in BP affect central levels of ET-1. A sustained increase in BP decreased circulating ET-1 levels in both plasma and 'I CSF. The concentration of ET-1 decreased by 64% in the CSF and by 40% in plasma.
Previous reports documented the effects of a number of different factors on systemic circulating endothelin levels. The concentration of ET-1 in plasma is increased in cardiogenic shock45 and congestive heart failure.46 In addition, plasma ET-1 levels are affected by postural changes and body fluid status. 47 We have recently observed a marked increase in immunoreactive endothelin after infusion of endotoxin.28 Similarly, chronic infusion of endothelin in rats produces a sustained increase in BP,48 whereas in humans, endothelin-secreting tumors are associated with hypertension.49 Although the effects of these factors on brain endothelin levels are unknown, our experiments with sinoaortic-denervated animals indicate that ET-1 concentration in the CSF is modulated by the baroreflex. In sinoaortic-denervated rats, the pressor effect of phenylephrine failed to effect reflex bradycardia and ET-1 levels in the CSF. These studies may also indicate that CSF endothelin reflects primarily spillover from neuronal tissue. However, further investigation will be needed to exclude the possibility that endothelin is actively secreted into the CSF and to determine whether the effects of an ET antagonist are affected by sinoaortic denervation.
Intracisternal administration of ET-1 (10 pmol) evoked a biphasic response in BP. The initial hypotensive response was followed by sustained hypertension. Because HR decreased during these two phases, it is unclear whether this bradycardia played a prominent FIGURE 9 . Cardiovascular effects of administration ofendothelin-1 into the rostroventrolateral medulla ofa normotensive Sprague-Dawley rat. The tracings represent the effects of a microinjection of 1 pmol endothelin-l (indicated by the arrow) on blood pressure (BP) and integrated renal sympathetic nerve activity. The tracings at the left were done before and immediately after administration of endothelin-l. The tracings at the right correspond to the effects observed after 6 minutes ofendothelin-1 administration. The recordings were made at a paper speed of 10 the importance of studying the actions of endothelin in specific brain nuclei. The first synapse of the baroreflex is located in the NTS, and activation of neuronal groups in this nucleus modulates parasympathetic and sympathetic tone. 34 Our results demonstrate that microinjection of ET-1 into the NTS causes a reduction in BP and HR. The bradycardic effect was somewhat more pronounced than the decrease in BP. Both effects, however, peaked at the 2-pmol dose. These cardiovascular effects, in addition, can be completely reproduced in the same animal if an appropriate interval period is allowed between microinjections (.30 minutes). Hashim and Tadepalli50 have recently published data demonstrating similar hypotensive effects of ET-1 in the NTS. This study further supports the conclusion that the NTS is not directly involved in the pressor effects of this endothelin isoform.
The AP is the most caudal circumventricular organ. In addition to lacking a functional blood-brain barrier, the AP has relevant neuronal connections with the adjacent NTS. 54 Conceivably, circulating ET could gain direct access to neuronal elements within this structure and evoke pressor actions. In our present studies, however, only modest hypotensive and bradycardic effects were observed. Under similar experimental conditions, another group reported a pressor effect with equivalent doses of ET-1 in the AP.25 Part of this discrepancy could be explained by the total volume in which ET-1 was microinjected. In our study, endothelin was administered in a volume not exceeding 60 nl. In contrast, Ferguson and Smith25 used a much larger volume of administration (total volume, 1,000 nl in several microinjections). The importance of controlling the volume of administration in stereotaxic microinjection studies has been noted by several investigators. Talman The initial pressor effect of intra-RVLM administration of ET-1 is likely to be related to activation of sympathetic tone. Our model, which assumes unchanged afferent nerve activity, clearly demonstrated an increase in efferent RSNA after ET-1 microinjection. This effect preceded the pressor effect. Others have shown that the increase in BP after intracerebroventricular administration of endothelin can be antagonized by a-adrenergic receptor antagonists22 and correlates with an increase in urinary excretion of norepinephrine. 57 This indicates that at least part of the central pressor effects of endothelin are the result of changes in sympathetic outflow. The mechanism of the subsequent hypotensive phase, however, is less clear. We excluded withdrawal of sympathetic tone during this phase, as we observed instead a pronounced increase in RSNA. This increase in sympathetic nerve traffic could be interpreted as a reflex response, attempting to compensate for the hypotension and bradycardia characteristic of this phase. Although non-receptor-mediated effects in the RVLM decrease BP (microinjection of local anesthetics or lesioning of RVLM neurons), they do not result in cardiovascular impairment when applied unilaterally. 36 It is conceivable that the hypotensive and bradycardic effects of ET-1 that preceded death may well be due to selective impairment of respiratory function within the RVLM.
We explored this last possibility in a set of experiments that evaluated some of the respiratory effects of ET-1 microinjection into the RVLM. Immediately after ET-1 administration, we did not observe changes in Rf. During the hypotensive phase, however, Rf increased without significant hypoxia or changes in Pco2 or pH. In the animals in which cardiorespiratory collapse was observed, Rf remained increased in spite of a progressive decrease in BP and HR. This seems to indicate that the cardiovascular effects of the initial phase cannot be explained by impairment of respiratory function. This concept is further supported by the results obtained in animals with artificial ventilation. In artificially ventilated animals, the initial BP response to low ET-1 doses was not significantly different from that in spontaneously breathing rats. On the other hand, none of the animals with artificial ventilation died, and BP and HR eventually returned to basal levels.
Although some authors have suggested that ET-3 is the neural form of endothelin,14 very few studies have addressed the effects of this isoform in central cardiovascular regulation. In the NTS, low doses of ET-3 increased BP and HR. These effects were different from those of ET-1 in the same nucleus (depressor) and further support the notion of different subtypes of endothelin receptors. Early pharmacological studies in isolated vessels also indicated different potencies for these two endothelin isoforms.14,15,58 More recently, different groups have identified two different endothelin receptors.16,17 The affinity for one subtype of ET-1 (ETA) is considerably higher than the affinity for ET-3. In the other subtype (ETB), ET-1 and ET-3 have similar affinity. It is not known whether specific receptor subtypes exist for ET-3. However, the different pharmacological profile in the NTS may suggest that the pressor effects in this nucleus are selective for this isoform. In contrast, in the AP, both endothelin isoforms elicited similar cardiovascular effects. This would suggest activation of the same subtype of endothelin receptor. It is interesting to note, however, that the highest doses of ET-1 did not significantly modify BP or HR, whereas similar doses of ET-3 had a pronounced hypotensive and bradycardic effect.
In the RVLM, ET-3 increased BP and HR without a clear dose-related effect. The increase in BP was more pronounced than the modest hypertensive effect seen with ET-1 in the same area. In spite of this, no cardiovascular or respiratory impairment was observed after intra-RVLM ET-3 administration.
This study did not investigate the effects of either ET4 or ET-3 microinjections on regional blood flow. Others have documented that after intracerebroventricular administration of ET-1, renal blood flow decreased for up to 90 minutes. 50 No data are available for the effects of endothelin on regional blood flow after intra-NTS or intra-RVLM microinjections. This should be elucidated in future experiments.
The potent effects of endothelin on isolated vessels raise the possibility that some of the cardiovascular actions of centrally administered endothelin are related to medullary ischemia. Additionally, administration of large doses of ET-1 (1 ,ug) has been shown to produce neurotoxic effects and brain lesions. 59 In our studies, however, it is unlikely that any of these mechanisms explain the cardiovascular effects of endothelin. For instance, microinjection of ET-1 into the NTS evoked a decrease in BP and HR. If ET-1 were producing nonspecific neuronal effects in the NTS, we might have observed an increase in BP similar to the one observed after administration of local anesthetics or impairment of NTS function.60 Furthermore, administration of ET-1 at the doses used in this study did not significantly affect the response to glutamate in the NTS.
Another indication of the specificity of the endothelin response comes from our studies with microinjection of phenylephrine. No effects were apparent with this vasopressor agent except for a mild decrease in HR after the highest dose in the NTS. It is important to note, however, that intravenous bolus administration of the highest dose of phenylephrine used in the present study produces 
